Janssen Signs Licensing Agreement with Vedanta for IBD Treatment Development

Janssen Signs Licensing Agreement with Vedanta for IBD Treatment Development
Philadelphia-based Janssen Biotech, Inc., a biotechnology company with a focus on developing diagnostic assays using monoclonal antibody technology, has just signed a strategic licensing agreement with Vedanta Biosciences, an expert in microbiology and immunology. The agreement covers licensing terms for Vedanta's flagship microbiome drug candidate for autoimmune diseases, VE202, and stipulates that Janssen proceed with development and subsequent commercialization, in
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *